Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to -$100.2 million.

  • Theravance Biopharma's Cash from Investing Activities fell 47615.95% to -$100.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.2 million, marking a year-over-year decrease of 211098.31%. This contributed to the annual value of $12.3 million for FY2024, which is 13756.92% up from last year.
  • Theravance Biopharma's Cash from Investing Activities amounted to -$100.2 million in Q3 2025, which was down 47615.95% from -$36.3 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Cash from Investing Activities ranged from a high of $1.1 billion in Q3 2022 and a low of -$100.2 million during Q3 2025
  • Its 5-year average for Cash from Investing Activities is $60.6 million, with a median of $10.8 million in 2021.
  • In the last 5 years, Theravance Biopharma's Cash from Investing Activities surged by 310452.32% in 2022 and then tumbled by 8275238.1% in 2024.
  • Over the past 5 years, Theravance Biopharma's Cash from Investing Activities (Quarter) stood at $10.8 million in 2021, then surged by 261.8% to $39.2 million in 2022, then plummeted by 101.73% to -$677000.0 in 2023, then soared by 2416.99% to $15.7 million in 2024, then plummeted by 739.08% to -$100.2 million in 2025.
  • Its last three reported values are -$100.2 million in Q3 2025, -$36.3 million for Q2 2025, and $30.6 million during Q1 2025.